76893-49-7

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 576-26-1 2.6-dimethylphenol 

Downstream Products

• 1311138-03-0 N'-{6-[(2,6-dimethylphenyl)oxy]-3-pyridinyl}-D-alaninamide 
• 1311138-02-9 1,1-dimethylethyl [(1R)-2-({6-[(2,6-dimethylphenyl)oxy]-3-pyridinyl}amino)-1-methyl-2-oxoethyl]carbamate 
• 928003-13-8 6-[(2,6-dimethylphenyl)oxy]-3-pyridinamine 
• 1311136-94-3 3-{6-[(2,6-dimethylphenyl)oxy]-3-pyridinyl}-5,5-dimethyl-2,4-imidazolidinedione 
• 1311136-78-3 (5R)-3-{6-[(2,6-dimethylphenyl)oxy]-3-pyridinyl}-5-methyl-2,4-imidazolidinedione 
• 1311138-40-5 N'-{6-[(2,6-dimethylphenyl)oxy]-3-pyridinyl}-2-methylalaninamide 
• 1311138-36-9 1,1-dimethylethyl [2-({6-[(2,6-dimethylphenyl)oxy]-3-pyridinyl}amino)-1,1-dimethyl-2-oxoethyl]carbamate 

Relevant academic research and scientific papers

IMIDAZOLIDINEDIONE DERIVATIVES

The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.